M J Mozziconacci Selected Research

ponatinib

3/2015

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M J Mozziconacci Research Topics

Disease

2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2020 - 01/2020
2	Acute Promyelocytic Leukemia 08/2000 - 08/2000
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2015
1	Primary Myelofibrosis (Myelosclerosis) 01/2015
1	Neoplasms (Cancer) 08/2010
1	Chromosome Aberrations (Chromosome Abnormalities) 08/2004
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2004

Drug/Important Bio-Agent (IBA)

2	RetinoidsIBA 08/2000 - 08/2000
1	ponatinibIBA 03/2015
1	CalreticulinIBA 01/2015
1	Staphylococcal Protein A (Protein A)IBA 08/2010
1	Imatinib Mesylate (Gleevec)FDA Link 08/2004
1	bcr-abl Fusion ProteinsIBA 08/2004

Therapy/Procedure

3	Therapeutics 04/2020 - 08/2004
1	Precision Medicine 01/2020